23.24
전일 마감가:
$24.06
열려 있는:
$23.54
하루 거래량:
116.12K
Relative Volume:
0.23
시가총액:
$320.66M
수익:
-
순이익/손실:
$-19.48M
주가수익비율:
-15.87
EPS:
-1.4641
순현금흐름:
$-8.59M
1주 성능:
-13.80%
1개월 성능:
-9.13%
6개월 성능:
+90.02%
1년 성능:
+93.68%
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
GLSI
Greenwich Lifesciences Inc
|
23.14 | 333.34M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.50 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Analysis Recap: Is SPRY stock showing strong momentumQuarterly Market Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January - MarketBeat
How interest rate cuts could boost Greenwich LifeSciences Inc. stockJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Avoiding Lag: Real-Time Signals in (GLSI) Movement - Stock Traders Daily
How buybacks impact Greenwich LifeSciences Inc. stock valueWall Street Watch & AI Powered Market Entry Ideas - mfd.ru
Aug Update: Will Greenwich LifeSciences Inc stock benefit from M A2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Is Greenwich LifeSciences Inc. stock trending bullishRate Hike & Smart Money Movement Tracker - mfd.ru
Analyst Upgrade: Is Lavoro Limiteds growth already priced inJuly 2025 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for GLSI Earnings - MarketBeat
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsJuly 2025 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% – Here’s What Happened - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat
Greenwich LifeSciences: Strengthened Liquidity and Robust GP2 Data Support Reiterated Buy and $50 Target - TipRanks
Discipline and Rules-Based Execution in GLSI Response - Stock Traders Daily
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Will Greenwich LifeSciences Inc. benefit from current market trendsTrade Signal Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Greenwich LifeSciences reports $12.5 million cash balance - Investing.com
Greenwich LifeSciences reports $12.5 million cash balance By Investing.com - Investing.com Nigeria
Greenwich LifeSciences provides update on Flamingo-01 cash burn rate and financing strategy - marketscreener.com
Greenwich LifeSciences, Inc. Reports Positive Financial Updates and Progress on FLAMINGO-01 Phase III Trial - Quiver Quantitative
Greenwich Lifesciences Provides Update On Flamingo-01 Cash Burn Rate And Financing Strategy - TradingView
Biotech Greenwich LifeSciences raises $7M in 3 weeks for breast cancer trial - Stock Titan
FDA Approval Boosts Greenwich LifeSciences Stock Sharply - timothysykes.com
Treasury Yields: Will Greenwich LifeSciences Inc benefit from current market trendsMarket Volume Report & Low Risk Entry Point Tips - baoquankhu1.vn
Greenwich: GP2 Vaccine MilestoneWhat FDA Manufacturing Approval Means For Investors - Seeking Alpha
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases - Yahoo Finance
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
FDA approves commercial GP2 lot for Greenwich’s breast cancer trial By Investing.com - Investing.com Canada
Why Did Greenwich Lifesciences Stock Soar Pre-Market Today? - Menafn.com
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? - Asianet Newsable
GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits
Greenwich LifeSciences stock soars after FDA approves commercial GP2 in trial - Investing.com Canada
Greenwich gets FDA nod for commercially made product candidate - Seeking Alpha
Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial - TradingView
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 - The Manila Times
FDA approves first GP2 batch for breast cancer trial, 200,000 doses - Stock Titan
Morning Market Movers: IOTR, SXTP, GLSI, RAYA See Big Swings - RTTNews
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
Greenwich LifeSciences stockholders reelect board and auditor - MSN
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock By Investing.com - Investing.com South Africa
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
그리니치 주식 (GLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
자본화:
|
볼륨(24시간):